New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Search
Spiriva® Respimat®
An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
HER2 TKI, Zongertinib
HER2 TKI, Zongertinib
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Agile working as a mindset
How does an agile mindset foster innovation? Read about collaboration, user-centricity and rapid learning cycles
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
Digital solution for individualized diabetes care
With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.
Microbial Manufacturing Platform for Non-Platform Proteins
Microbial Manufacturing Platform for Non-Platform Proteins
Social Media Disclaimer
Social Media Disclaimer
Our products for COPD
Metacam® Pets
meloxicam
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Revolutionizing drug development
Our scientists are leveraging the "digital twins"-technology to revolutionize biotherapeutic drug development.
Transforming pig farming through AI
With our livestock farming technology based on sound analytics, we are improving pig farm practices, producing healthier pigs and a better farm economy.
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Imagine: Ecological stoves safeguard family health in Mexico
With Fondo Para la Paz, we’ve developed ecological stoves for safer indoor cooking, enhancing respiratory health for rural Mexican families
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Transboundary animal diseases and veterinary preparedness
What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease